Proliferative diabetic retinopathy is characterised by neovascularisation at the optic disc or in the peripheral retina. Recurrent vitreous haemorrhage and its sequelae and traction retinal detachment cause visual loss. It is the commonest cause of blindness between the ages of 30 and 65 years.' Several controlled trials have proved the benefit of photocoagulation in the treatment of proliferative diabetic retinopathy.2 The largest of these was the Diabetic Retinopathy Study (DRS), which showed that a single session of photocoagulation reduced the incidence of severe visual loss (defined as a visual acuity of less than 5/200) in treated eyes. 2 The beneficial effect of photocoagulation is associated with the regression of retinopathy risk factors (RRF), particularly new vessels on the disc (NVD).' The question whether additional treatment is beneficial was not addressed by these trials, but it is widespread clinical practice to apply further laser photocoagulation until regression of new vessels occurs. How many burns can be applied? We present a group of 20 patients (28 eyes) who were included in the study because their disc new vessels required an excess of 5000 burns to induce regression, an end point which had not been achieved with lesser numbers of burns. Fig. 1 .
The complications of diabetic retinopathy and the degree of new vessel regression produced by photocoagulation are shown in Table 2 . Ten eyes of six patients had focal (exudative) maculopathy, either before or during panretinal photocoagulation.
Fourteen eyes of 10 patients had cystoid maculopathy. In five of these eyes (1R, 1L, 7R, 13L, and 18L) it was present before, and in the remaining nine eyes (3R, 5R, 5L, 6L, 9R, 9L, 14R, 14L, and 17R) it developed during panretinal photocoagulation. Nine of the 28 eyes received macular laser treatment. Eyes 1R and 1L had ischaemic maculopathy. Eyes 9R and 9L were aphakic. Three eyes (2R, 3L, and 6L) had rubeosis iridis, and this resolved after photocoagulation. Eye 4R had a superotemporal traction retinal vitreous haemorrhage. One eye had transient shallowing of the anterior chamber without angle closure following photocoagulation. There were no inadvertently placed photocoagulation bums or their associated complications. Complete regression of disc new vessels was the end result in 18 eyes of 13 patients (64% of eyes). In seven eyes of seven patients (25% of eyes) the disc new vessels regressed completely, but varying degrees of gliosis of the optic disc remained. In three eyes of three patients (11% of eyes) residual, fine, flat new vessels with fibrosis, which remained static for at least six months, were present on the surface of the optic disc.
Discussion
We have presented a group of patients in whom a large amount of argon laser photocoagulation over an extended period was required in order to induce regression of new vessels. The treatment protocol for argon laser photocoagulation in the DRS specified a single session of 800 to 1600 burns of 500 Ftm and 0-1 s duration, or 500 to 1000 bums of 100 tim.6 This was shown to result in a lower incidence of severe visual Given that additional panretinal photocoagulation is desirable, how should it be organised? It seems reasonable to allow time between sessions for regression to occur. In a prospective study of 50 eyes treated with a single session of 1200 argon laser burns according to the DRS protocol Doft and Blakenship found that eyes with no regression of retinopathy risk factors at 3 weeks had only a 36% chance of showing regression at 6 months."' They achieved some degree of regression of NVD in 86% of eyes at 3 weeks and in 82% at 6 months. This suggests that a decision regarding further treatment can be made reasonably soon after the initial session. In our group of patients the mean interval between treatment sessions was 12*4 weeks, which is probably longer than necessary.
It is desirable to achieve regression of blood vessels as soon as possible owing to the risk of vitreous haemorrhage which can hamper further treatment. However, this must be balanced against other factors, including the tolerance of the patient and the increased incidence of transient complications such as exudative retinal detachment, choroidal detachment, and angle closure when many burns are applied in a single session." Of these complications we experienced only one episode of marked shallowing of the anterior chamber without angle closure. The low occurrence of these complications in our patients may be a reflection of our 4 The maximum number of contiguous but nonoverlapping 500 iim argon laser burns that may be applied to a retina has been estimated as 5500.12 All but four of the eyes in this study received in excess of 5500 and one (eye 10R) received more than twice this figure. There are several reasons why this should be. Firstly, the size of the histological lesion varies according to the exposure and may be smaller for lightly applied bums.'3 Secondly, the edge of a previous bum as seen through the contact lens and slit-lamp may not correspond to the limit of the area of histological damage. Thirdly, a large proportion of burns were applied overlapping previous burns. This is not necessarily undesirable and indeed is essential if a confluent area of treatment is to be achieved by means of circular bums (Fig. 2) . A typical example of a retina which has received such extensive treatment is shown in Fig. 3 .
Other factors which could affect the number of burns required to induce regression of new vessels include the presence of opacities in the media, the degree of choroidal pigmentation, variations in the energy density at the retinal surface,'4'5 the operators' accommodation, the astigmatism introduced by the contact lens, and the depth of focus of the system.'5 Argon laser photocoagulation is associated with several adverse effects. These may be divided into complications, such as angle closure, macular oedema, and foveal bums, and inevitable side effects such as loss of visual field and colour discrimination.'6 Transient complications have already been discussed. Macular oedema occurred in nine of our patients following panretinal photocoagulation, but its development was not related to the total number of bums applied or to the mean number of burns per session, and all patients in this group had posttreatment visual acuities of 6/18 or better. It is unlikely that the patients presented here will have normal visual fields or colour vision, and this will form the subject of a further study. However, it is noteworthy that despite large amounts of photocoagulation they have retained functional vision with excellent visual acuity, 25 eyes (89%) having 6/18 or better. 
